Realtime | Geld | Brief | Zeit |
---|---|---|---|
6,520 | 7,180 | 20:01 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.05. | Asseco SEE and BNP Paribas to join mWIG40 index, Grenevia and Selvita to leave (opinion) | 7 | PAP | ||
22.05. | Selvita pharma sees slowdown in contracting; H2 marked by uncertainty | 2 | PAP | ||
22.05. | Selvita pharma backlog for 2025 at PLN 249.9 mln | 1 | PAP | ||
SELVITA Aktie jetzt für 0€ handeln | |||||
22.05. | Selvita pharma posts PLN 1.0 mln attributable net loss in Q1 '25, below expectations | 3 | PAP | ||
27.03. | Selvita S.A.: Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025 | 278 | PR Newswire | KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024... ► Artikel lesen | |
21.11.24 | Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future | 197 | PR Newswire | KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published... ► Artikel lesen | |
24.09.24 | Selvita S.A.: Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024 | 438 | PR Newswire | KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,740 | -1,31 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,116 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
COSCIENS BIOPHARMA | 2,840 | -2,74 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
HALOZYME THERAPEUTICS | 45,780 | +2,01 % | Halozyme Therapeutics in den Russell 1000 Index aufgenommen | ||
ABCELLERA BIOLOGICS | 3,118 | +5,48 % | AbCellera-Aktionäre genehmigen Vorstandswahl und Wirtschaftsprüfer | ||
GLOW LIFETECH | 0,019 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Provides Commercial Update; Expands to 1000+ Stores in Ontario and Achieves #2 Oil Brand with MOD | Toronto, Ontario--(Newsfile Corp. - June 23, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update reflecting its... ► Artikel lesen | |
BIO-RAD LABORATORIES | 204,30 | -2,90 % | Disruption! Ab jetzt wird alles anders: BioNxt Solutions, BioNTech, Bio-Rad Laboratories | Der Ausbruch der Corona-Pandemie hat vieles verändert. Frei nach dem Motto "Einfach mal machen" setzten Unternehmen wie BioNTech auf die mRNA-Technologie. Der Erfolg inklusive Milliardenumsätzen folgte... ► Artikel lesen | |
AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd. - 6-K, Report of foreign issuer | ||
WHITEHAWK THERAPEUTICS | 1,620 | +1,89 % | Whitehawk Therapeutics, Inc.: Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
MINERVA NEUROSCIENCES | 1,310 | -10,27 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates | BURLINGTON, Mass., May 13, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates... ► Artikel lesen | |
APPLIED THERAPEUTICS | 0,292 | +6,38 % | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting | Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute... ► Artikel lesen | |
GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs, Inc. - S-1/A, General form for registration of securities |